109 related articles for article (PubMed ID: 27642091)
1. Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group.
Xu L; Wilson RA; Laetsch TW; Oliver D; Spunt SL; Hawkins DS; Skapek SX
Sci Rep; 2016 Sep; 6():33429. PubMed ID: 27642091
[TBL] [Abstract][Full Text] [Related]
2. Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
Ivanov M; Laktionov K; Breder V; Chernenko P; Novikova E; Telysheva E; Musienko S; Baranova A; Mileyko V
J Transl Med; 2017 Jan; 15(1):22. PubMed ID: 28137276
[TBL] [Abstract][Full Text] [Related]
3. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
4. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
[TBL] [Abstract][Full Text] [Related]
5. Detection of
Anyanwu NCJ; Ella EE; Aminu M; Kazeem HM
J Immunoassay Immunochem; 2019; 40(6):605-616. PubMed ID: 31538838
[TBL] [Abstract][Full Text] [Related]
6. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
7. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
[TBL] [Abstract][Full Text] [Related]
11. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
[TBL] [Abstract][Full Text] [Related]
12. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.
Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D
Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
14. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
16. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
17. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutation analysis in melanoma using targeted next generation sequencing.
Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
[TBL] [Abstract][Full Text] [Related]
19. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
20. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
